BRIEF: CSPC Pharma profit dips on falling drug revenue

1093.HK

CSPC Pharmaceutical Group Ltd. (1093.HK) warned on Thursday that is net profit for the first nine months of this year fell about 16% compared with a year earlier.

It blamed the decline on falling revenue for its oncology and cardiovascular therapeutic drugs, which were down about 18% and 11%, respectively, year-on-year during the period. Those declines were partially offset by a 4% rise in revenue from its nervous system therapeutic drug sales. CSPC’s shares fell 13% to HK$5 in early Friday trade.

By A. Au

To subscribe to Bamboo Works free weekly newsletter, click here

,

Related Articles

RELATED ARTICLES

  1. Earnings blow for CSPC Pharma
    Earnings blow for CSPC Pharma as the state drives a hard bargain
    1093.HK
  2. Hengrui Pharma accelerates bid for global brand status
    600276.SHG
  3. Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
  4. Dida reverses into revenue contraction, falling profits
    2559.HK
  5. BRIEF: Tsingtao Brewery profit dips on sluggish beer market
    0158.HK 600600.SHG
  6. ZG Group set to forge Hong Kong’s second De-SPAC listing
    2572.HK
  7. Mixue pours up strong growth in China’s overheated bubble tea market
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

Recent Articles

Illustration of the rebound of Chinese fintech lenders

A fintech lender rebound, and a hotel mess

Fintech lenders are entering a new golden era, with Jiayin reporting 46% growth for its core consumer lending business in last year's fourth quarter and forecasting similar gains this year. What's driving this rebound? And hotelier H World is still trying to fix a German acquisition from 2019 that wiped out its profit in the fourth quarter of last year. Will the Chinese hotelier be able to turn around this money-losing offshore asset?
JFIN.US HTHT.US